Rhythm Pharmaceuticals (RYTM) shares rose more than 10% in recent trading activity on Monday after Goldman Sachs upgraded the company's rating to buy from...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
| Address | 222 Berkeley Street Boston, Massachusetts 02116-3748 |
| Phone | +1.857.264.4280 |
| Number of Employees | 54 |
| Recent SEC Filing | 08/03/2022 10-Q |
| Chairman, President & Chief Executive Officer | David P. Meeker |
| Chief Financial Officer & Treasurer | Hunter C. Smith |
| Vice President-Medical Affairs | Brieana Buckley |
| Chief Technical Officer | Joseph Shulman |
| Price Open | $24.50 |
| Previous Close | $24.25 |
| 52 Week Range | $3.04 - 27.29 |
| Market Capitalization | $1.2 B |
| Shares Outstanding | 50.7 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 11/01/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$3.49 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | -1,310.60% |
| Return on Equity | -67.73% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
